Advertisement

High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde—comment

  • Luigi Ferini-StrambiEmail author
  • Marco Sforza
  • Andrea Galbiati
CE - LETTER TO THE EDITOR
  • 15 Downloads

Dear Editor,

We read with great interest the article by Faccini et al. [1] entitled “High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde”. In this work, the authors retrospectively assessed 1112 patients affected by substance abuse disorder characterized by the abuse of high-dose benzodiazepines (BDZs) and admitted in a tertiary referral addiction unit for detoxification. Among all the available BDZs, lormetazepam was the most common compound with a prevalence that increased from 2003 to 2018. Importantly, lormetazepam abusers significantly differed from other BDZ abusers. The most striking results was that 96.7% of lormetazepam abusers took oral solutions, in contrast, two-thirds of other BDZ abusers took tablets. As reported by the authors, these data underline that drug formulation dramatically impacts on the potential for abuse.

Chronic insomnia is the most frequent sleep disorder encountered in clinical practice. Cognitive behavioral therapy of insomnia...

Notes

Compliance with ethical standards

Conflict of interest

Prof. Luigi Ferini-Strambi received fees from Philips-Respironics, UCB Pharma, Lundbeck, Pfizer, Valeas, Italfarmaco. Dr. Marco Sforza and Dr. Andrea Galbiati have nothing to disclose.

Statement of human and animal rights

This study was conducted in accordance with the ethical standards of our Institutional committee on Human experimentation.

Informed consent

All participants provided written informed consent to the experimental procedure which was previously approved by the local ethical committee.

References

  1. 1.
    Faccini M, Tamburin S, Casari R, Morbioli L, Lugoboni F (2019) High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde. Intern Emerg Med.  https://doi.org/10.1007/s11739-019-02101-8 Google Scholar
  2. 2.
    Riemann D, Baglioni C, Bassetti C, Bjorvatn B, Dolenc Groselj L, Ellis JG, Espie CA, Garcia-Borreguero D, Gjerstad M, Gonçalves M, Hertenstein E, Jansson-Fröjmark M, Jennum PJ, Leger D, Nissen C, Parrino L, Paunio T, Pevernagie D, Verbraecken J, Weeß HG, Wichniak A, Zavalko I, Arnardottir ES, Deleanu OC, Strazisar B, Zoetmulder M, Spiegelhalder K (2017) European guideline for the diagnosis and treatment of insomnia. J Sleep Res 26(6):675–700CrossRefGoogle Scholar
  3. 3.
    Sokya M (2017) Treatment of benzodiazepine dependence. N Engl J Med 376:1147–1157CrossRefGoogle Scholar
  4. 4.
    Manconi M, Ferri R, Miano S, Maestri M, Bottasini V, Zucconi M, Ferini-Strambi L (2017) Sleep architecture in insomniacs with severe benzodiazepine abuse. Clin Neurophysiol 128:875–881CrossRefGoogle Scholar
  5. 5.
    Faccini M, Leone R, Pajusco B, Quaglio G, Casari R, Albiero A, Donati M, Lugoboni F (2012) Lormetazepam addiction: data analysis from an Italian medical unit for addiction. Risk Manag Healthc Policy 5:43–48Google Scholar

Copyright information

© Società Italiana di Medicina Interna (SIMI) 2019

Authors and Affiliations

  • Luigi Ferini-Strambi
    • 1
    • 2
    Email author
  • Marco Sforza
    • 1
    • 2
  • Andrea Galbiati
    • 1
    • 2
  1. 1.Department of Clinical Neurosciences, Neurology, Sleep Disorders CenterIRCCS San Raffaele Scientific InstituteMilanItaly
  2. 2.“Vita-Salute” San Raffaele University, Faculty of PsychologyMilanItaly

Personalised recommendations